A US start-up company has claimed that transfusions of plasma from donors under the age of 25 may reduce the risk of several major diseases associated with ageing, such as Alzheimer’s.
Their ongoing clinical trial measures a plethora of blood biomarkers before and one-month after the transfusion. So far, 70 participants over the age of 35 years have paid to be involved in the study.
“I don’t want to say the word panacea, but here’s something about teenagers,” said Jesse Karmazin, founder of startup company Ambrosia, told New Scientist. “Whatever is in young blood is causing changes that appear to make the ageing process reverse.”
Biomarkers being tested include cancer specific antigens, cytokines, proteinases, growth factors and immunoglobulins. The trial has been criticised for having no placebo group.
Read more about the story here.